{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:06:29Z","timestamp":1753891589209,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81820108014","81901277","82071407","82171396"],"award-info":[{"award-number":["81820108014","81901277","82071407","82171396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFE0114400"],"award-info":[{"award-number":["2018YFE0114400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>Myasthenia gravis (MG) is a T cell-dependent antibody-mediated autoimmune disorder that can seriously affect patients' quality of life. However, few studies have focused on the severity of MG. Moreover, existing therapeutic efforts, including those targeting biomarkers for MG, remain unsatisfactory. Therefore, it is vital that we investigate the pathogenesis of MG and identify new biomarkers that can not only evaluate the severity of the disease but also serve as potential therapeutic targets. Long noncoding RNA LINC00680 has been found to be associated with the progression of a variety of diseases as a competing endogenous RNA (ceRNA). However, the specific role of LINC00680 in MG has yet to be clarified. Here, we aimed to investigate the association between LINC00680 and the severity of MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Bioinformatics tools, quantitative real-time PCR, Western blotting, and luciferase assays were selected to investigate key signaling pathways and RNA expression in patients with MG. The Quantitative MG Score scale and the MG Composite scale were used to evaluate the severity of MG in the included patients. Cell viability assays and flow cytometry analysis were selected to analyze cell proliferation and apoptosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with control subjects, the expression levels of LINC00680 and mitogen-activated protein kinase 1 (MAPK1) in peripheral blood mononuclear cells of patients with MG were both upregulated; the levels of miR-320a were downregulated. A positive correlation was detected between LINC00680 expression and the severity of MG. Luciferase reporter assays identified that LINC00680 acts as a target for miR-320a. The <jats:italic>in vitro<\/jats:italic> analysis confirmed that LINC00680 regulates the expression of MAPK1 by sponging miR-320a. Finally, the functional analysis indicated that LINC00680 promoted Jurkat cell proliferation and inhibited cellular apoptosis by sponging miR-320a.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LINC00680 may be associated with the severity of MG as a ceRNA by sponging miR-320a to upregulate MAPK1. These findings suggest that LINC00680 may represent a potential biomarker which evaluates the severity of MG and may serve as a therapeutic target.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.833062","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T04:45:31Z","timestamp":1655786731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["LncRNA LINC00680 Acts as a Competing Endogenous RNA and Is Associated With the Severity of Myasthennia Gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","article-title":"MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1","volume":"33","author":"Cheng","year":"2013","journal-title":"J Clin Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis \u2014 autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","article-title":"Myasthenia gravis and the neuromuscular junction","volume":"26","author":"Querol","year":"2013","journal-title":"Curr Opin Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Poea-Guyon","year":"2005","journal-title":"J Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature."},{"key":"B12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Ther Adv Neurol Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1006\/clim.1999.4822","article-title":"Myocytes respond to both interleukin-4 and interferon-gamma: cytokine responsiveness with the potential to influence the severity and course of experimental myasthenia gravis","volume":"94","author":"Stegall","year":"2000","journal-title":"Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-Reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study","volume":"97","author":"Petersson","year":"2021","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1960","DOI":"10.1038\/cddis.2015.267","article-title":"Downregulation of miR-320a\/383-sponge-like long non-coding RNA NLC1-C (narcolepsy candidate-region 1 genes) is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation","volume":"6","author":"Lu","year":"2015","journal-title":"Cell Death Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nature12943","article-title":"The evolution of lncRNA repertoires and expression patterns in tetrapods","volume":"505","author":"Necsulea","year":"2014","journal-title":"Nature."},{"key":"B18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.gpb.2016.03.007","article-title":"Long non-coding RNAs and their roles in non-small-cell lung cancer","volume":"14","author":"Wei","year":"2016","journal-title":"Genomics Proteomics Bioinformatics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","article-title":"Long noncoding RNAs in cancer pathways","volume":"29","author":"Schmitt","year":"2016","journal-title":"Canc Cell."},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ncrna6030025","article-title":"LncRNAs in non-small-cell lung cancer","volume":"6","author":"Ginn","year":"2020","journal-title":"Noncoding RNA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1021\/acschemneuro.0c00150","article-title":"LncRNA GAS5 and miR-137 polymorphisms and expression are associated with multiple sclerosis risk: mechanistic insights and potential clinical impact","volume":"11","author":"Senousy","year":"2020","journal-title":"ACS Chem Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11010-019-03681-x","article-title":"LncRNA MEG3 inhibits the inflammatory response of ankylosing spondylitis by targeting miR-146a","volume":"466","author":"Li","year":"2020","journal-title":"Mol Cell Biochem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1111\/jcmm.16438","article-title":"Association of LncRNA-GAS5 gene polymorphisms and PBMC LncRNA-GAS5 level with risk of systemic lupus erythematosus in Chinese population","volume":"25","author":"Liu","year":"2021","journal-title":"J Cell Mol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.clim.2017.08.008","article-title":"IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis though HLA-DRB1","volume":"183","author":"Luo","year":"2017","journal-title":"Clin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e12886","DOI":"10.1111\/sji.12886","article-title":"LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1\/PD-L1 expression in patients with myasthenia gravis-related thymoma","volume":"92","author":"Hu","year":"2020","journal-title":"Scand J Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/cancers12051245","article-title":"Mechanisms of long non-coding RNAs in cancers and their dynamic regulations","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cell.2011.07.014","article-title":"et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language?","volume":"146","author":"Salmena","year":"2011","journal-title":"Cell."},{"key":"B28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrg.2016.20","article-title":"Endogenous microRNA sponges: evidence and controversy","volume":"17","author":"Thomson","year":"2016","journal-title":"Nat Rev Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-020-1133-9","article-title":"LncRNA JPX\/miR-33a-5p\/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt\/beta-catenin signaling","volume":"19","author":"Pan","year":"2020","journal-title":"Mol Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-020-01206-5","article-title":"LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303\/PTBP3 axis","volume":"19","author":"Liang","year":"2020","journal-title":"Mol Cancer."},{"key":"B31","first-page":"D135","article-title":"RNALocate: a resource for RNA subcellular localizations","volume":"45","author":"Zhang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13046-021-01854-5","article-title":"LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3","volume":"40","author":"Shu","year":"2021","journal-title":"J Exp Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"8183","DOI":"10.2147\/OTT.S259232","article-title":"LINC00680 promotes the progression of non-small cell lung cancer and functions as a sponge of miR-410-3p to enhance HMGB1 expression","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","article-title":"StarBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA, and protein-RNA interaction networks from large-scale CLIP-Seq data.","volume":"42","author":"Li","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"D239","DOI":"10.1093\/nar\/gks1246","article-title":"DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long noncoding RNAs","volume":"41","author":"Paraskevopoulou","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"D902","DOI":"10.1093\/nar\/gkw1038","article-title":"NSDNA: a manually curated database of experimentally supported ncRNAs associated with nervous system diseases","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1002\/jcb.27838","article-title":"The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis","volume":"120","author":"Kong","year":"2019","journal-title":"J Cell Biochem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9918","DOI":"10.1111\/jcmm.15906","article-title":"Analysis of association between MALAT1 haplotype and the severity of normal-tension glaucoma (NTG)","volume":"25","author":"Yue","year":"2021","journal-title":"J Cell Mol Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/15384047.2019.1702405","article-title":"LncRNA FTX inhibition restrains osteosarcoma proliferation and migration via modulating miR-320a\/TXNRD1","volume":"21","author":"Huang","year":"2020","journal-title":"Cancer Biol Therapy."},{"key":"B40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13104-020-05001-9","article-title":"Downregulation of circulating miR-320a and target gene prediction in patients with diabetic retinopathy","volume":"13","author":"Prado","year":"2020","journal-title":"BMC Res Notes."},{"key":"B41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41419-020-02896-x","article-title":"LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a\/neuropilin-1 axis","volume":"11","author":"Zhu","year":"2020","journal-title":"Cell Death Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ijc.29544","article-title":"Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma","volume":"137","author":"Wen","year":"2015","journal-title":"Int J Cancer."},{"key":"B43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbapap.2005.08.017","article-title":"MAPK signalling pathways as molecular targets for anti-inflammatory therapy\u2013from molecular mechanisms to therapeutic benefits","volume":"1754","author":"Kaminska","year":"2005","journal-title":"Biochim Biophys Acta."},{"key":"B44","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1165\/ajrcmb.20.4.3420","article-title":"Both Erk and p38 kinases are necessary for cytokine gene transcription","volume":"20","author":"Carter","year":"1999","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1054\/jocn.2001.1028","article-title":"Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis","volume":"9","author":"Yoshikawa","year":"2002","journal-title":"J Clin Neurosci."},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201848007","article-title":"MiR-181a regulates CD4 T cell activation and differentiation by targeting IL-2 in the pathogenesis of myasthenia gravis","volume-title":"Eur J Immunol.","author":"Liu","year":"2019"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.833062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T04:45:37Z","timestamp":1655786737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.833062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":46,"alternative-id":["10.3389\/fneur.2022.833062"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.833062","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"article-number":"833062"}}